Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients IDeate-01 phase 2 trial currently...

Karnataka High Court Quashes BJP Slogan FIR, Ads Case, Sets 24-Hour Custody Rule
Tamil Nadu Government Allows Six Daily Film Shows Starting at 6 AM
Ranji Trophy: How Nagwaswalla, Gaja, and Patel Put Gujarat in Control Against Kerala
Fielding Lapses in Kanpur Show Why Uttar Pradesh Cannot Rely Solely on Batting Power
Ashok Leyland share price jumps 11.65% on 23% rise in October CV sales 




























